H7T2 Stock Overview
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
HUTCHMED (China) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£3.16 |
| 52 Week High | UK£3.96 |
| 52 Week Low | UK£2.10 |
| Beta | 0.75 |
| 11 Month Change | -16.40% |
| 3 Month Change | 3.95% |
| 1 Year Change | -5.95% |
| 33 Year Change | -45.98% |
| 5 Year Change | -22.55% |
| Change since IPO | -44.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| H7T2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.6% | -0.3% | 0.8% |
| 1Y | -6.0% | -18.3% | 8.6% |
Return vs Industry: H7T2 exceeded the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: H7T2 underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| H7T2 volatility | |
|---|---|
| H7T2 Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: H7T2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: H7T2's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,970 | Wei-Guo Su | www.hutch-med.com |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.
HUTCHMED (China) Limited Fundamentals Summary
| H7T2 fundamental statistics | |
|---|---|
| Market cap | €2.83b |
| Earnings (TTM) | -€40.06m |
| Revenue (TTM) | €583.01m |
4.8x
P/S Ratio-70.6x
P/E RatioIs H7T2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| H7T2 income statement (TTM) | |
|---|---|
| Revenue | US$610.81m |
| Cost of Revenue | US$658.26m |
| Gross Profit | -US$47.45m |
| Other Expenses | -US$5.48m |
| Earnings | -US$41.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | -7.77% |
| Net Profit Margin | -6.87% |
| Debt/Equity Ratio | 10.9% |
How did H7T2 perform over the long term?
See historical performance and comparison